7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... Note: Systemic antifungals ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... (Varivax™), 2 doses ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... please refer to Table ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
injection) for 1–4 doses ... intraocular levels of drug ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... • Therapeutic drug ... #treatment #antifungals ... #comparison #table ... #pharmacology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
adjusting the dose ... differential #algorithm #management ... #table #foamed ... #criticalcare #icu ... #clinical #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
months or • RFB (dose ... Please refer to the table ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology